Table 2.
Baseline patient characteristics and outcome of randomized controlled studies included in the meta-analysis
| Author | Total subjects | Tocilizumab | SOC | Outcomes | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | Male n (%) | Age (median (range) or mean ± SD | Mortality n (%) | n | Male n (%) | Age (median (range) or mean ± SD | Mortality n (%) | |||
| (Salvarani et al., 2021) | 126 | 60 | 40 (66.7%) | 61.5 (51.5-73.5) | 2 (3.3%) | 66 | 37 (56%) | 60 (54-69) | 1 (1.5%) | Mortality, ICU admission, progression to MV |
| (Salama et al., 2021) | 377 | 249 | 150 (60%) | 56 ± 14.3 | 26 (10.4%) | 128 | 73 (57%) | 55.6 ± 14.9 | 11 (8.6%) | Mortality, composite outcome (MV or death by day 28) |
| (Hermine et al., 2021) | 130 | 63 | 44 (69.8%) | 64 (57.1-74.3) | 7 (11.1%) | 67 | 44 (65.7%) | 63.3 (57.1-72.3) | 8 (11.9%) | Mortality, proportion needing noninvasive or MV, composite outcome |
| (Rosas et al., 2021) | 438 | 294 | 205 (69.7%) | 60.9 ± 14.6 | 58 (19.7%) | 144 | 101 (70%) | 60.6 ± 13.7 | 28 (19.4%) | Clinical failure (defined as death, initiation of MV or ICU admission) |
| (Soin et al., 2021) | 179 | 91 | 76 (83.5%) | 56 (47-63) | 11 (12.1%) | 88 | 76 (86%) | 54 (43-63) | 15 (17%) | Mortality, incidence of MV up to day 21 |
| (Stone et al., 2020) | 243 | 161 | 96 (59.6%) | 61.1 (46.4-69.7) | 9 (5.6%) | 82 | 45 (54.8) | 56.5 (44.7-67.8) | 3 (3.7%) | Mortality, ICU admission, composite outcome |
| (Veiga et al., 2021) | 129 | 65 | 44 (67.7%) | 57.4 ± 15.7 | 14 (21.5%) | 64 | 44 (69%) | 57.5 ± 13.5 | 6 (9.4%) | Mortality, progression to MV, composite outcome |
| (Gordon et al., 2021) | 755 | 353 | 261 (73.9%) | 61.5 ± 12.5 | 87 (24.6%) | 402 | 283 (70%) | 61.1 ± 12.8 | 160 (39.8%) | Mortality, composite outcome |
| (Horby et al., 2021) | 4116 | 2,022 | 1,335 (66%) | 63.3 ± 13.7 | 596 (29.5) | 2,094 | 1437 (68.6%) | 63.9 ± 13.6 | 694 (33.1%) | Mortality by day 28, composite outcome |